![A, Change in controlled attenuation parameter (CAP) after treatment... | Download Scientific Diagram A, Change in controlled attenuation parameter (CAP) after treatment... | Download Scientific Diagram](https://www.researchgate.net/publication/327419010/figure/fig1/AS:677387847077888@1538513256102/A-Change-in-controlled-attenuation-parameter-CAP-after-treatment-with-dapagliflozin-5.png)
A, Change in controlled attenuation parameter (CAP) after treatment... | Download Scientific Diagram
![ACC 2021: AstraZeneca's Farxiga failed to help COVID-19 patients, but it's safe for them to use | Fierce Pharma ACC 2021: AstraZeneca's Farxiga failed to help COVID-19 patients, but it's safe for them to use | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1621102632/Farxiga.jpg/Farxiga.jpg?VersionId=tKwGafVnkpAGsElslL8L7lhELjuoe0XG)
ACC 2021: AstraZeneca's Farxiga failed to help COVID-19 patients, but it's safe for them to use | Fierce Pharma
![IJMS | Free Full-Text | SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection IJMS | Free Full-Text | SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection](https://www.mdpi.com/ijms/ijms-23-03107/article_deploy/html/images/ijms-23-03107-g001.png)
IJMS | Free Full-Text | SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
![Sodium‐Glucose Co‐Transporter 2 (SGLT2) Inhibitor Dapagliflozin Stabilizes Diabetes‐Induced Atherosclerotic Plaque Instability | Journal of the American Heart Association Sodium‐Glucose Co‐Transporter 2 (SGLT2) Inhibitor Dapagliflozin Stabilizes Diabetes‐Induced Atherosclerotic Plaque Instability | Journal of the American Heart Association](https://www.ahajournals.org/cms/asset/76fe1020-2b59-47d6-812c-8afaa871b300/jah37007-fig-0001.png)
Sodium‐Glucose Co‐Transporter 2 (SGLT2) Inhibitor Dapagliflozin Stabilizes Diabetes‐Induced Atherosclerotic Plaque Instability | Journal of the American Heart Association
![Serum high-molecular-weight adiponectin and response to dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease | Journal of Investigative Medicine Serum high-molecular-weight adiponectin and response to dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease | Journal of Investigative Medicine](https://jim.bmj.com/content/jim/69/7/1324/F2.large.jpg)
Serum high-molecular-weight adiponectin and response to dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease | Journal of Investigative Medicine
![AstraZeneca's diabetes drug Farxiga nabs coveted kidney disease nod, way ahead of rival Jardiance | Fierce Pharma AstraZeneca's diabetes drug Farxiga nabs coveted kidney disease nod, way ahead of rival Jardiance | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1619989374/Farxiga%2010mg.jpg?VersionId=dHWdb1WN.E.nqpjVWVnOqyBuZk7JIEKD)
AstraZeneca's diabetes drug Farxiga nabs coveted kidney disease nod, way ahead of rival Jardiance | Fierce Pharma
![ACC 2021: AstraZeneca's Farxiga failed to help COVID-19 patients, but it's safe for them to use | Fierce Pharma ACC 2021: AstraZeneca's Farxiga failed to help COVID-19 patients, but it's safe for them to use | Fierce Pharma](https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1621102632/Farxiga.jpg/Farxiga.jpg?VersionId=tKwGafVnkpAGsElslL8L7lhELjuoe0XG)